HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shenzhen Chipscreen Biosciences (688321.CH) - Risks Outweigh Opportunities

Pre IPO Shukun Technology - Obvious Strength in Technology/Products but Commercialization Is the Key

China Healthcare Weekly (Jun.10) - Medical Service Price Reform, Medical Device CXO, Lockdown Lifted

Pre-IPO Beijing Airdoc Technology - The Strength and the Concerns

Pre-IPO Infervision Medical Technology - Insights on Industry, Business and Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Beijing Airdoc Technology / Equity Capital Markets

<ul class="">
<li>The performance of stock price of <a href="https://www.smartkarma.com/entities/beijing-airdoc-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:33524:1" rel="noopener">Beijing Airdoc Technology (2251 HK)</a> after listing in HKEX was not satisfactory.</li>
<li>The real turning point for the commercialization of AI medical imaging market has not arrived.</li>
<li>Together with other concerns such as fierce competition, data security issue, the lack of medical insurance coverage and insufficient recognition in hospital market, etc., we are conservative about the outlook of Airdoc at the current stage.</li>
</ul>


The performance of stock price of Beijing Airdoc Technology (2251 HK) after listing in HKEX was not satisfactory.
The real turning point for the commercialization of AI medical imaging market has not arrived.
Together with other concerns such as fierce competition, data security issue, the lack of medical insurance coverage and insufficient recognition in hospital market, etc., we are conservative about the outlook of Airdoc at the current stage.


Beijing Airdoc Technology (2251.HK) - Here Are the Concerns